Thalocan Research Innovations Creative Director, Paul Stroili discusses our recent company conference in Los Angeles, recognizing just some of the many who share our mission of revolutionizing the clinical assessment of dermatological diseases.
Our CEO, Eric Zudak will be representing Thalocan Research Innovations at The EADV Congress, the globally recognized international meeting focused on dermatology and venereology. We always learn so much, in fact – our most innovative product was conceived during an expert presentation at EADV 2023 in Berlin! That product, LAMA, (https://www.thalocan.com/lama/) is now study-ready for…
“The current set up for HS lesion counting in clinical trials and routine practice is far from ideal. Counting multiple lesions in multiple body sites takes time and there is high risk for error. Thalocan’s Lesion Area Mapping Assistant Trial enables sponsors to undertake quality control from the images and site personnel can assess images…
Thalocan Research Innovations has partnered with Arash Mostaghimi, MD, MPA, MPH to develop a comprehensive training for the BETA and BELA to accompany The Severity of Alopecia Tool (SALT), training for a robust and high quality Alopecia assessment curriculum. Our mission is to support clinical raters with a clear understanding of the scoring criteria for…
